Beyaert Simon, Machiels Jean-Pascal, Schmitz Sandra
Institut de Recherche Expérimentale et Clinique (IREC), Pôle MIRO, Université Catholique de Louvain (UCLouvain), 1200 Brussels, Belgium.
Department of Medical Oncology, King Albert II Cancer Institute, St-Luc University Hospital, 1200 Brussels, Belgium.
Cancers (Basel). 2021 Nov 30;13(23):6041. doi: 10.3390/cancers13236041.
In 2019, the FDA approved pembrolizumab, a monoclonal antibody targeting PD-1, for the first-line treatment of recurrent or metastatic head and neck cancers, despite only a limited number of patients benefiting from the treatment. Promising effects of therapeutic vaccination led the FDA to approve the use of the first therapeutic vaccine in prostate cancer in 2010. Research in the field of therapeutic vaccination, including possible synergistic effects with anti-PD(L)1 treatments, is evolving each year, and many vaccines are in pre-clinical and clinical studies. The aim of this review article is to discuss vaccines as a new therapeutic strategy, particularly in the field of head and neck cancers. Different vaccination technologies are discussed, as well as the results of the first clinical trials in HPV-positive, HPV-negative, and EBV-induced head and neck cancers.
2019年，美国食品药品监督管理局（FDA）批准了帕博利珠单抗（一种靶向程序性死亡受体1（PD-1）的单克隆抗体）用于复发性或转移性头颈癌的一线治疗，尽管只有少数患者从该治疗中获益。治疗性疫苗显示出的有前景的效果促使FDA在2010年批准了首款用于前列腺癌的治疗性疫苗。治疗性疫苗领域的研究，包括与抗程序性死亡受体配体1（PD(L)1）治疗可能产生的协同效应，每年都在不断发展，许多疫苗正处于临床前和临床研究阶段。这篇综述文章的目的是讨论疫苗作为一种新的治疗策略，特别是在头颈癌领域。文中讨论了不同的疫苗接种技术，以及人乳头瘤病毒（HPV）阳性、HPV阴性和EB病毒（EBV）诱发的头颈癌的首批临床试验结果。
Zotero 插件